Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) Forward Dividend Yield %: 0.00% (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09637 Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
5 GF Score
Price HK$25.00
! 1 Warning Sign
View Full Analysis

What is Alebund Pharmaceuticals (Jiangsu) Forward Dividend Yield %?

Alebund Pharmaceuticals (Jiangsu) HKSE:09637 -2.87% 5 Forward Dividend Yield % is 0.00% as of Sep. 10, 2026. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review. Among 502 Drug Manufacturers companies, Alebund Pharmaceuticals (Jiangsu) ranks worse than 199202.99% on this metric.

As of today (2026-09-10), the Forward Annual Dividend Yield of Alebund Pharmaceuticals (Jiangsu) is 0.00%.

As of today (2026-09-10), the Trailing Annual Dividend Yield of Alebund Pharmaceuticals (Jiangsu) is 0.00%.

HKSE:09637's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.045
* Ranked among companies with meaningful Forward Dividend Yield % only.

Alebund Pharmaceuticals (Jiangsu)'s Dividends per Share for the six months ended in Dec. 2025 was HK$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Alebund Pharmaceuticals (Jiangsu)  (HKSE:09637) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Alebund Pharmaceuticals (Jiangsu) Forward Dividend Yield % Related Terms


HKSE:09637 vs LLY, JNJ, ABBV: Forward Dividend Yield % Comparison

For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alebund Pharmaceuticals (Jiangsu) Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s Forward Dividend Yield % falls into.


HKSE:09637
5GF Score
Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alebund Pharmaceuticals (Jiangsu) Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Forward Dividend Yield % of 0.00% as of Sep. 10, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. According to the industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #999999 out of 502 companies in the Drug Manufacturers industry.
Is Alebund Pharmaceuticals (Jiangsu)'s Forward Dividend Yield % too high?
Alebund Pharmaceuticals (Jiangsu)'s current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #999999 out of 502 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Forward Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #999999 out of 502 companies for Forward Dividend Yield %. This places Alebund Pharmaceuticals (Jiangsu) in the lower half of its industry. The industry median Forward Dividend Yield % is 2.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.05, based on 502 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alebund Pharmaceuticals (Jiangsu)'s current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Forward Dividend Yield % is 0.00% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alebund Pharmaceuticals (Jiangsu) Business Description

Address No. 7 Jinzhuang Road, Building 7, High-tech Zone, Gaoxin District, Hanjiang District, Jiangsu Province, Yangzhou, CHN
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score

Get the complete analysis for HKSE:09637

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$25.00
Price